Discovery is the key to advancing human health. Find out how our leading researchers are pioneering new, breakthrough solutions to some of the world’s most challenging health problems.
Led by CEO John Valliant, the company that develops next-generation precision cancer medicines will become a wholly owned subsidiary of AstraZeneca and continue its operations at its state-of-the-art facility at McMaster Innovation Park.
McMaster researcher John Eikelboom co-leads the pan-African REVIVE trial, which will test a low-cost antibiotic as an effective tool to address the HIV crisis in Africa.
The Canadian Society of Chemistry's Melanie O’Neill Award recognizes Whitney's study of the molecular mechanisms of antibacterial toxins.